- Home
- CVKD vs MDAI Comparison
CVKD vs MDAI Comparison
Compare CVKD & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MDAI
- Stock Information
- Founded
- CVKD 2022
- MDAI 2013
- Country
- CVKD United States
- MDAI United States
- Employees
- CVKD N/A
- MDAI N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MDAI Medical/Dental Instruments
- Sector
- CVKD Health Care
- MDAI Health Care
- Exchange
- CVKD Nasdaq
- MDAI Nasdaq
- Market Cap
- CVKD 31.5M
- MDAI 27.8M
- IPO Year
- CVKD 2023
- MDAI N/A
- Fundamental
- Price
- CVKD $16.75
- MDAI $1.24
- Analyst Decision
- CVKD Strong Buy
- MDAI Strong Buy
- Analyst Count
- CVKD 1
- MDAI 2
- Target Price
- CVKD $32.00
- MDAI $4.75
- AVG Volume (30 Days)
- CVKD 22.9K
- MDAI 436.0K
- Earning Date
- CVKD 05-08-2025
- MDAI 05-06-2025
- Dividend Yield
- CVKD N/A
- MDAI N/A
- EPS Growth
- CVKD N/A
- MDAI N/A
- EPS
- CVKD N/A
- MDAI N/A
- Revenue
- CVKD N/A
- MDAI $29,581,000.00
- Revenue This Year
- CVKD N/A
- MDAI N/A
- Revenue Next Year
- CVKD N/A
- MDAI $102.58
- P/E Ratio
- CVKD N/A
- MDAI N/A
- Revenue Growth
- CVKD N/A
- MDAI 63.83
- 52 Week Low
- CVKD $5.70
- MDAI $0.82
- 52 Week High
- CVKD $22.90
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- CVKD 49.23
- MDAI 41.89
- Support Level
- CVKD $14.10
- MDAI $1.18
- Resistance Level
- CVKD $17.39
- MDAI $1.28
- Average True Range (ATR)
- CVKD 1.57
- MDAI 0.10
- MACD
- CVKD 0.04
- MDAI 0.02
- Stochastic Oscillator
- CVKD 54.19
- MDAI 50.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.